Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

BACKGROUND: Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Montano, Ryan, Thompson, Ruth, Chung, Injae, Hou, Huagang, Khan, Nadeem, Eastman, Alan
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878047/
https://ncbi.nlm.nih.gov/pubmed/24359526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-604
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires